PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33971494-9	2021	Finally, inhibition of PGC1alpha/SIRT3 pathway by 3-TYP in hyperglycemic H9c2-cells reversed the beneficial effects of combination therapy on cardiomyocytes injury and NF-kappaB/NLRP3/IL-1beta expression, without affecting TLR4/MyD88 expression.	3-TYP	50-55	PPARG coactivator 1 alpha	Rattus norvegicus	23-32
33971494-9	2021	Finally, inhibition of PGC1alpha/SIRT3 pathway by 3-TYP in hyperglycemic H9c2-cells reversed the beneficial effects of combination therapy on cardiomyocytes injury and NF-kappaB/NLRP3/IL-1beta expression, without affecting TLR4/MyD88 expression.	3-TYP	50-55	sirtuin 3	Rattus norvegicus	33-38
33971494-9	2021	Finally, inhibition of PGC1alpha/SIRT3 pathway by 3-TYP in hyperglycemic H9c2-cells reversed the beneficial effects of combination therapy on cardiomyocytes injury and NF-kappaB/NLRP3/IL-1beta expression, without affecting TLR4/MyD88 expression.	3-TYP	50-55	NLR family, pyrin domain containing 3	Rattus norvegicus	178-183
33971494-9	2021	Finally, inhibition of PGC1alpha/SIRT3 pathway by 3-TYP in hyperglycemic H9c2-cells reversed the beneficial effects of combination therapy on cardiomyocytes injury and NF-kappaB/NLRP3/IL-1beta expression, without affecting TLR4/MyD88 expression.	3-TYP	50-55	interleukin 1 alpha	Rattus norvegicus	184-192
33971494-9	2021	Finally, inhibition of PGC1alpha/SIRT3 pathway by 3-TYP in hyperglycemic H9c2-cells reversed the beneficial effects of combination therapy on cardiomyocytes injury and NF-kappaB/NLRP3/IL-1beta expression, without affecting TLR4/MyD88 expression.	3-TYP	50-55	toll-like receptor 4	Rattus norvegicus	223-227
33971494-9	2021	Finally, inhibition of PGC1alpha/SIRT3 pathway by 3-TYP in hyperglycemic H9c2-cells reversed the beneficial effects of combination therapy on cardiomyocytes injury and NF-kappaB/NLRP3/IL-1beta expression, without affecting TLR4/MyD88 expression.	3-TYP	50-55	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	228-233
34869361-3	2021	In this study, we used 3-TYP to inhibit SIRT3 and found that this inhibition aggravated oxidative damage in the hair cells of mice with NIHL.	3-TYP	23-28	sirtuin 3	Mus musculus	40-45
34869361-4	2021	Moreover, 3-TYP reduced the enzymatic activity and deacetylation levels of superoxide dismutase 2 (SOD2).	3-TYP	10-15	superoxide dismutase 2, mitochondrial	Mus musculus	75-97
34869361-4	2021	Moreover, 3-TYP reduced the enzymatic activity and deacetylation levels of superoxide dismutase 2 (SOD2).	3-TYP	10-15	superoxide dismutase 2, mitochondrial	Mus musculus	99-103
34795840-7	2021	However, the cardioprotective effects of TBM were largely abolished by a SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP).	3-TYP	89-123	sirtuin 3	Homo sapiens	73-78
34795840-7	2021	However, the cardioprotective effects of TBM were largely abolished by a SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP).	3-TYP	125-130	sirtuin 3	Homo sapiens	73-78
33892299-8	2021	In addition, after intraperitoneal injection of the SIRT3 inhibitor 3-TYP in rats, the protective effect of liquiritin against UVB damage was found to be diminished.	3-TYP	68-73	sirtuin 3	Rattus norvegicus	52-57
34273723-9	2021	After inhibiting Sirt3 expression with SiRNA targeting Sirt3 (Si-Sirt3) and 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP), the positive role of Anti-134 was apparently reversed.	3-TYP	76-110	sirtuin 3	Mus musculus	17-22
34503544-8	2021	Furthermore, the inhibitory effects of DHM on PA-induced autophagy arrest and oxidative stress were eliminated when pretreated with a SIRT3 inhibitor 3-TYP or conducted in HepG2/ATG4B+- cells, suggesting that SIRT3 and ATG4B were involved in DHM-induced benefits.	3-TYP	150-155	sirtuin 3	Homo sapiens	209-214
34503544-8	2021	Furthermore, the inhibitory effects of DHM on PA-induced autophagy arrest and oxidative stress were eliminated when pretreated with a SIRT3 inhibitor 3-TYP or conducted in HepG2/ATG4B+- cells, suggesting that SIRT3 and ATG4B were involved in DHM-induced benefits.	3-TYP	150-155	autophagy related 4B cysteine peptidase	Homo sapiens	219-224
34526903-7	2021	Continued cellular experiments using 3-TYP, an inhibitor of Sirtuin 3 (SIRT3), revealed a loss of cellular protection by luteolin and a decrease in collagen, suggesting that luteolin acts by targeting and promoting SIRT3.	3-TYP	37-42	sirtuin 3	Homo sapiens	60-69
34526903-7	2021	Continued cellular experiments using 3-TYP, an inhibitor of Sirtuin 3 (SIRT3), revealed a loss of cellular protection by luteolin and a decrease in collagen, suggesting that luteolin acts by targeting and promoting SIRT3.	3-TYP	37-42	sirtuin 3	Homo sapiens	71-76
34526903-7	2021	Continued cellular experiments using 3-TYP, an inhibitor of Sirtuin 3 (SIRT3), revealed a loss of cellular protection by luteolin and a decrease in collagen, suggesting that luteolin acts by targeting and promoting SIRT3.	3-TYP	37-42	sirtuin 3	Homo sapiens	215-220
34118791-7	2021	Additionally, 3-TYP (a selective SIRT3 inhibitor) and SIRT3 siRNA inhibited the above protective effects of melatonin as well as the upregulation of SIRT3 and the decrease of SOD2 acetylation but did not affect the p-Akt/Akt ratio.	3-TYP	14-19	sirtuin 3	Mus musculus	33-38
34118791-7	2021	Additionally, 3-TYP (a selective SIRT3 inhibitor) and SIRT3 siRNA inhibited the above protective effects of melatonin as well as the upregulation of SIRT3 and the decrease of SOD2 acetylation but did not affect the p-Akt/Akt ratio.	3-TYP	14-19	sirtuin 3	Mus musculus	149-154
34118791-7	2021	Additionally, 3-TYP (a selective SIRT3 inhibitor) and SIRT3 siRNA inhibited the above protective effects of melatonin as well as the upregulation of SIRT3 and the decrease of SOD2 acetylation but did not affect the p-Akt/Akt ratio.	3-TYP	14-19	superoxide dismutase 2, mitochondrial	Mus musculus	175-179
35409099-5	2022	Interestingly, 3-TYP caused an increase in gene expression of adipocyte-specific cytokines including IL6, resistin, and TNF-alpha.	3-TYP	15-20	interleukin 6	Homo sapiens	101-104
35409099-5	2022	Interestingly, 3-TYP caused an increase in gene expression of adipocyte-specific cytokines including IL6, resistin, and TNF-alpha.	3-TYP	15-20	tumor necrosis factor	Homo sapiens	120-129
35409099-11	2022	These results indicate that, via insulin signaling regulation, Sirt3 activation by HNK improves insulin resistance, while Sirt3 inhibition by 3-TYP might precipitate insulin resistance.	3-TYP	142-147	insulin	Homo sapiens	33-40
35409099-11	2022	These results indicate that, via insulin signaling regulation, Sirt3 activation by HNK improves insulin resistance, while Sirt3 inhibition by 3-TYP might precipitate insulin resistance.	3-TYP	142-147	sirtuin 3	Homo sapiens	63-68
35409099-11	2022	These results indicate that, via insulin signaling regulation, Sirt3 activation by HNK improves insulin resistance, while Sirt3 inhibition by 3-TYP might precipitate insulin resistance.	3-TYP	142-147	sirtuin 3	Homo sapiens	122-127
35409099-11	2022	These results indicate that, via insulin signaling regulation, Sirt3 activation by HNK improves insulin resistance, while Sirt3 inhibition by 3-TYP might precipitate insulin resistance.	3-TYP	142-147	insulin	Homo sapiens	166-173
35013907-20	2022	The anti-oxidant and anti-inflammatory effects of TREM2 were partially abrogated by SIRT3 antagonist 3-TYP (p < 0.05 and p < 0.05, respectively).	3-TYP	101-106	triggering receptor expressed on myeloid cells 2	Mus musculus	50-55
35013907-20	2022	The anti-oxidant and anti-inflammatory effects of TREM2 were partially abrogated by SIRT3 antagonist 3-TYP (p < 0.05 and p < 0.05, respectively).	3-TYP	101-106	sirtuin 3	Mus musculus	84-89
35096052-9	2022	Administration of the selective SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine resulted in increased damage to the cochlea, including loss of ribbon synapses and hair cells, apoptosis of hair cells, more production of ROS, and reduced mitochondrial membrane potential.	3-TYP	48-82	sirtuin 3	Homo sapiens	32-37
34033817-9	2021	To clarify whether TBM provides protec-tion via SIRT3, we injected a specific SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) into mice before TBM treatment.	3-TYP	94-128	sirtuin 3	Mus musculus	78-83
33420900-12	2021	The effect of Rb1 against high glucose-induced mitochondria-related apoptosis was restrained by 3-TYP (P<0.05 or P<0.01).	3-TYP	96-101	RB transcriptional corepressor 1	Homo sapiens	14-17
33790896-6	2021	Correspondingly, melatonin treatment triggered SOD2 deacetylation and increased SOD2 activity and subsequently reduced oxidative stress; this amelioration of oxidative stress by melatonin was blocked by the SIRT3-selective inhibitor, 3-TYP, and was independent of SIRT1.	3-TYP	234-239	sirtuin 3	Mus musculus	207-212
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	187-221	sirtuin 3	Homo sapiens	36-41
33480219-7	2021	SIRT3 inhibitor 3-TYP was used to further confirm whether muscone worked via the augmentation of SIRT3.	3-TYP	16-21	sirtuin 3	Rattus norvegicus	0-5
33480219-12	2021	With 3-TYP inhibiting SIRT3, the protective effects of muscone in H9c2 cardiomyocytes and SD rats were all significantly alleviated.	3-TYP	5-10	sirtuin 3	Rattus norvegicus	22-27
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	187-221	superoxide dismutase 2	Homo sapiens	63-67
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	187-221	superoxide dismutase 2	Homo sapiens	110-114
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	187-221	sirtuin 3	Homo sapiens	171-176
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	223-228	superoxide dismutase 2	Homo sapiens	110-114
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	223-228	sirtuin 3	Homo sapiens	36-41
33015038-9	2020	More importantly, caffeine enhanced SIRT3 activity and reduced SOD2 acetylation, thereby leading to increased SOD2 activity, which could be reversed by treatment with the SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) in vitro and in vivo.	3-TYP	223-228	sirtuin 3	Homo sapiens	171-176
32546969-12	2020	Moreover, the decreased expression of SIRT3 and FoxO3a in A/R-injured H9c2 cells was abrogated by melatonin, but these beneficial effects were attenuated by the MT2 antagonist 4-P-PDOT or the SIRT3 inhibitor 3-TYP and enhanced by the MT2 agonist IIK7.	3-TYP	208-213	sirtuin 3	Rattus norvegicus	192-197
32141452-6	2020	The cytoprotective effect of AR-C17 was abolished by the SIRT3 inhibitor 3-TYP, which led to increased cell apoptosis.	3-TYP	73-78	sirtuin 3	Rattus norvegicus	57-62
32546969-12	2020	Moreover, the decreased expression of SIRT3 and FoxO3a in A/R-injured H9c2 cells was abrogated by melatonin, but these beneficial effects were attenuated by the MT2 antagonist 4-P-PDOT or the SIRT3 inhibitor 3-TYP and enhanced by the MT2 agonist IIK7.	3-TYP	208-213	sirtuin 3	Rattus norvegicus	38-43
32546969-12	2020	Moreover, the decreased expression of SIRT3 and FoxO3a in A/R-injured H9c2 cells was abrogated by melatonin, but these beneficial effects were attenuated by the MT2 antagonist 4-P-PDOT or the SIRT3 inhibitor 3-TYP and enhanced by the MT2 agonist IIK7.	3-TYP	208-213	forkhead box O3	Rattus norvegicus	48-54
30270436-10	2019	A sirtuin 3 (SIRT3) inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine or shRNA-mediated SIRT3 knockdown abolished the inhibitory effect of PNU-282987.	3-TYP	30-64	sirtuin 3	Homo sapiens	2-11
30270436-10	2019	A sirtuin 3 (SIRT3) inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine or shRNA-mediated SIRT3 knockdown abolished the inhibitory effect of PNU-282987.	3-TYP	30-64	sirtuin 3	Homo sapiens	13-18
31251943-7	2019	The cytoprotective effect of ICA was abolished in ROT-treated cells by SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP), along with a resultant decrease in PGC-1alpha expression.	3-TYP	87-121	sirtuin 3	Rattus norvegicus	71-76
30584213-8	2019	Further, the SIRT3 inhibitor 3-TYP effectively inhibited the initiation of mitophagy, as decreased expression of PINK1 and Parkin, decreased the LC3II/LC3I, enhanced the expression of MMP3 and MMP13, and decreased the expression of Collagen II.	3-TYP	29-34	sirtuin 3	Homo sapiens	13-18
30584213-8	2019	Further, the SIRT3 inhibitor 3-TYP effectively inhibited the initiation of mitophagy, as decreased expression of PINK1 and Parkin, decreased the LC3II/LC3I, enhanced the expression of MMP3 and MMP13, and decreased the expression of Collagen II.	3-TYP	29-34	PTEN induced kinase 1	Homo sapiens	113-118
30584213-8	2019	Further, the SIRT3 inhibitor 3-TYP effectively inhibited the initiation of mitophagy, as decreased expression of PINK1 and Parkin, decreased the LC3II/LC3I, enhanced the expression of MMP3 and MMP13, and decreased the expression of Collagen II.	3-TYP	29-34	matrix metallopeptidase 3	Homo sapiens	184-188
30584213-8	2019	Further, the SIRT3 inhibitor 3-TYP effectively inhibited the initiation of mitophagy, as decreased expression of PINK1 and Parkin, decreased the LC3II/LC3I, enhanced the expression of MMP3 and MMP13, and decreased the expression of Collagen II.	3-TYP	29-34	matrix metallopeptidase 13	Homo sapiens	193-198
30502252-4	2019	The rats were intraperitoneally injected with either the vehicle or a selective SIRT3 inhibitor (3-TYP) and scarified at different time points (4, 8, and 24 h after I/R).	3-TYP	97-102	sirtuin 3	Rattus norvegicus	80-85
30502252-7	2019	Moreover, SIRT3 suppression by 3-TYP treatment (comparing with the vehicle treatment group) aggravated AKI, as evidenced by increased indicators of oxidative stress (increased mitochondrial red fluorescence MitoSOX and decreased reduced glutathione/oxidized glutathione ratio, all P values < 0.01).	3-TYP	31-36	sirtuin 3	Rattus norvegicus	10-15
29760950-9	2018	In rats, GP improved HS-induced VH, which was repressed by 3MA and 3-(1H-1,2,3-triazol-4-yl)pyridine (3-TYP), a SIRT3 inhibitor.	3-TYP	67-100	sirtuin 3	Rattus norvegicus	112-117
28500761-10	2017	However, the cardioprotective effects of melatonin were largely abolished by the selective SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl)pyridine (3-TYP), suggesting that SIRT3 plays an essential role in mediating the cardioprotective effects of melatonin.	3-TYP	107-140	sirtuin 3	Rattus norvegicus	91-96
28500761-10	2017	However, the cardioprotective effects of melatonin were largely abolished by the selective SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl)pyridine (3-TYP), suggesting that SIRT3 plays an essential role in mediating the cardioprotective effects of melatonin.	3-TYP	107-140	sirtuin 3	Rattus norvegicus	166-171
28500761-10	2017	However, the cardioprotective effects of melatonin were largely abolished by the selective SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl)pyridine (3-TYP), suggesting that SIRT3 plays an essential role in mediating the cardioprotective effects of melatonin.	3-TYP	142-147	sirtuin 3	Rattus norvegicus	91-96
28500761-10	2017	However, the cardioprotective effects of melatonin were largely abolished by the selective SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl)pyridine (3-TYP), suggesting that SIRT3 plays an essential role in mediating the cardioprotective effects of melatonin.	3-TYP	142-147	sirtuin 3	Rattus norvegicus	166-171
26120888-10	2015	Moreover, 3-(1H-1,2,3-triazol-4-yl)pyridine, a confirmed selective SIRT3 inhibitor, blocked the melatonin-mediated suppression of autophagy by inhibiting SIRT3-SOD2 signaling.	3-TYP	10-43	sirtuin 3	Homo sapiens	67-72
26120888-10	2015	Moreover, 3-(1H-1,2,3-triazol-4-yl)pyridine, a confirmed selective SIRT3 inhibitor, blocked the melatonin-mediated suppression of autophagy by inhibiting SIRT3-SOD2 signaling.	3-TYP	10-43	sirtuin 3	Homo sapiens	154-159
26120888-10	2015	Moreover, 3-(1H-1,2,3-triazol-4-yl)pyridine, a confirmed selective SIRT3 inhibitor, blocked the melatonin-mediated suppression of autophagy by inhibiting SIRT3-SOD2 signaling.	3-TYP	10-43	superoxide dismutase 2	Homo sapiens	160-164